Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Johnson and Johnson...

    Johnson and Johnson seeks European Medicines Agency nod for Ebola Vaccine

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-08T09:45:58+05:30  |  Updated On 8 Nov 2019 9:45 AM IST
    Johnson and Johnson seeks European Medicines Agency nod for Ebola Vaccine

    JnJ said it submitted two marketing authorization applications to the European Medicines Agency (EMA) for its vaccine regimen targeting the Zaire strain of the Ebola virus, which most commonly causes outbreaks of the deadly disease.


    New Delhi: Johnson & Johnson (JnJ) said on Thursday it had filed for approval from European regulators for its two-dose experimental vaccine to protect against Ebola, less than a month after the agency recommended approval of Merck & Co Inc's vaccine.


    JnJ said it submitted two marketing authorization applications to the European Medicines Agency (EMA) for its vaccine regimen targeting the Zaire strain of the Ebola virus, which most commonly causes outbreaks of the deadly disease.


    The company's vaccine requires two injections administered about eight weeks apart, the first developed using J&J's technology and the second from Denmark-based biotech Bavarian Nordic A/S.


    Johnson & Johnson's applications are supported by data from over 10 studies that have tested the regimen in adults and children, the company said.


    The drugmaker added it was discussing with the Food and Drug Administration the dataset that would be required for U.S. approval.


    Since it first started in August 2018, the Ebola outbreak has killed more than 2,000 people, second only to the 2013-16 outbreak in West Africa that killed more than 11,300.


    Read Also: J&J CEO testified Baby Powder was safe 13 days before FDA bombshell


    The EMA's recommendation for approval in October of Merck's Ebola vaccine, taken as a single shot, was hailed by the World Health Organization as a "triumph for public health" that could save many lives.


    This month, health authorities in the Democratic Republic of Congo are introducing Johnson & Johnson's vaccine to counter the current outbreak in the country's eastern provinces, where Merck's vaccine is already in use.


    J&J's unit Janssen is also working in collaboration with the World Health Organization to enable registration of the Ebola vaccine regimen in African countries, the company said.


    Read Also: J&J passes the asbestos test, allowed to make baby powder in India

    EbolaEbola vaccineEMAEuropean Medicines AgencyEuropean regulatorsJ&JJnJJohnsonJohnson & JohnsonMerckUSFDAvaccineWHOWorld Health Organization
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok